Chronus Pharmaceuticals

Chronus Pharmaceuticals is a pre-clinical stage biotechnology and diagnostics company focused on improving the treatment and diagnosis of infectious diseases. The company's proprietary platform leverages deep knowledge of metabolic pathways, focused metabolite detection, and slow-binding drug-target kinetics to develop highly selective therapeutics and diagnostics. Chronus's pipeline includes an antibody-based diagnostic assay for pediatric tuberculosis (TB) and bacteria-specific positron emission tomography (PET) radiotracers, such as [18F]FNB, designed to detect deep-seated bacterial infections like prosthetic joint infections. Founded by researchers from Stony Brook University, the company operates out of the Long Island High Technology Incubator (LIHTI) in New York.